Faron, etusivu

releases and announcements

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

Regulatory

Faron announces strategic collaboration with The Institute for Cancer Research to launch BLAZE trial, targeting immunotherapy resistance in cancer

Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board

Regulatory

Faron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement

Regulatory

Faron presents updated BEXMAB data at ASH 2025: Deep and durable responses in HR-MDS with favorable safety profile

Faron Pharmaceuticals Ltd: Holding(s) in Company

Shareholder announcement Regulatory

Faron Pharmaceuticals Ltd: Registration of New Shares

Regulatory

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Regulatory

Faron Pharmaceuticals Ltd: Grant of Options

Insider Transaction Regulatory

Faron Pharmaceuticals Ltd: Appointment of CFO

Regulatory
PreviousNext
Back to top